Название продукции:5-bromo-2-methylpyrimidine

IUPAC Name:5-bromo-2-methylpyrimidine

CAS:7752-78-5
Молекулярная формула:C5H5BrN2
Чистота:97%
Номер в каталоге:CM104177
Молекулярная масса:173.01

Упаковочная единица Доступно для заказа Цена ($) Количество
CM104177-100g in stock ʼnǤǵ
CM104177-250g in stock Ľźʼn

Только для использования в НИОКР..

Форма запроса

   refresh    

Информация о продукции

Номер CAS:7752-78-5
Молекулярная формула:C5H5BrN2
Точка плавления:-
Smiles-код:CC1=NC=C(Br)C=N1
Плотность:
Номер в каталоге:CM104177
Молекулярная масса:173.01
Точка кипения:
Номер Mdl:MFCD07375143
Хранение:

Category Infos

Pyrimidines
Pyrimidine, also known as 1,3-diazobenzene, is a heterocyclic compound with the chemical formula C4H4N2. Pyrimidine is formed by substituting 2 nitrogen atoms for 2 carbons in the meta-position of benzene. It is a diazine and retains its aromaticity. Derivatives of pyrimidine widely exist in organic macromolecular nucleic acids, and many drugs also contain pyrimidine rings. In nucleic acids, three nucleobases are pyrimidine derivatives: cytosine, thymine and uracil. There are a variety of pyrimidine-containing drugs on the market, most of which are kinase inhibitors.

Column Infos

Voydeya
Voydeya (danicopan) has been approved in Japan for the treatment of paroxysmal nocturnal haemoglobinuria (PNH). Voydeya is the first drug in the class to be cleared for marketing anywhere in the world and has been licensed for use as an add-on therapy to C5 inhibitors, like its own Soliris (eculizumab) and Ultomiris (ravulizumab) products, in patients who don’t get a satisfactory response from C5 drugs alone. Voydeya (danicopan) is a first-in-class oral Factor D inhibitor. Voydeya has been granted Breakthrough Therapy designation by the US Food and Drug Administration and PRIority MEdicines (PRIME) status by the European Medicines Agency. Voydeya has also been granted Orphan Drug Designation in the US, EU and Japan for the treatment of PNH.